The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Causes of Death and Prognostic Factors in Multiple Endocrine Neoplasia Type 1: A Prospective Study Comparison of 106 MEN1/Zollinger-Ellison Syndrome Patients With 1613 Literature MEN1 Patients With or Without Pancreatic Endocrine Tumors
Open accessAbstract
Multiple endocrine neoplasia type 1 (MEN1) is classically characterized by the development of functional or nonfunctional hyperplasia or tumors in endocrine tissues (parathyroid, pancreas, pituitary, adrenal). Because effective treatments have been developed for the hormone excess state, which was a major cause of death in these patients in the past, coupled with the recognition that nonendocrine tumors increasingly develop late in the disease course, the natural history of the disease has changed. An understanding of the current causes of death is important to tailor treatment for these patients and to help identify prognostic factors; however, it is generally lacking.To add to our understanding, we conducted a detailed analysis of the causes of death and prognostic factors from a prospective long-term National Institutes of Health (NIH) study of 106 MEN1 patients with pancreatic endocrine tumors with Zollinger-Ellison syndrome (MEN1/ZES patients) and compared our results to those from the pooled literature data of 227 patients with MEN1 with pancreatic endocrine tumors (MEN1/PET patients) reported in case reports or small series, and to 1386 patients reported in large MEN1 literature series. In the NIH series over a mean follow-up of 24.5 years, 24 (23%) patients died (14 MEN1-related and 10 non-MEN1-related deaths). Comparing the causes of death with the results from the 227 patients in the pooled literature series, we found that no patients died of acute complications due to acid hypersecretion, and 8%-14% died of other hormone excess causes, which is similar to the results in 10 large MEN1 literature series published since 1995. In the 2 series (the NIH and pooled literature series), two-thirds of patients died from an MEN1-related cause and one-third from a non-MEN1-related cause, which agrees with the mean values reported in 10 large MEN1 series in the literature, although in the literature the causes of death varied widely. In the NIH and pooled literature series, the main causes of MEN1-related deaths were due to the malignant nature of the PETs, followed by the malignant nature of thymic carcinoid tumors. These results differ from the results of a number of the literature series, especially those reported before the 1990s. The causes of non-MEN1-related death for the 2 series, in decreasing frequency, were cardiovascular disease, other nonendocrine tumors > lung diseases, cerebrovascular diseases. The most frequent non-MEN1-related tumor deaths were colorectal, renal > lung > breast, oropharyngeal. Although both overall and disease-related survival are better than in the past (30-yr survival of NIH series: 82% overall, 88% disease-related), the mean age at death was 55 years, which is younger than expected for the general population.Detailed analysis of causes of death correlated with clinical, laboratory, and tumor characteristics of patients in the 2 series allowed identification of a number of prognostic factors. Poor prognostic factors included higher fasting gastrin levels, presence of other functional hormonal syndromes, need for >3 parathyroidectomies, presence of liver metastases or distant metastases, aggressive PET growth, large PETs, or the development of new lesions.The results of this study have helped define the causes of death of MEN1 patients at present, and have enabled us to identify a number of prognostic factors that should be helpful in tailoring treatment for these patients for both short- and long-term management, as well as in directing research efforts to better define the natural history of the disease and the most important factors determining long-term survival at present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Gibril, F., Schumann, M., Pace, A., & Jensen, R. T. (2004) · Medicine · doi:10.1097/01.md.0000112297.72510.32 · Cited by 313
Self-citationAdrenal involvement in multiple endocrine neoplasia type 1
Langer, P., Cupisti, K., Bartsch, D. K., Nies, C., Goretzki, P. E., Rothmund, M., & Röher, H. D. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6492-4 · Cited by 151
Adrenal lesion in multiple endocrine neoplasia type 1
Skogseid, B., Rastad, J., Gobl, A., Larsson, C., Backlin, K., Juhlin, C., Åkerström, G., & Öberg, K. (1995) · Surgery · doi:10.1016/s0039-6060(05)80117-5 · Cited by 111
Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review
Harring, T. R., Nguyen, N. T. N., Goss, J. A., & O'Mahony, C. A. (2011) · International Journal of Hepatology · doi:10.4061/2011/154541 · Cited by 69
Griniatsos, J. E., Dimitriou, N., Zilos, A., Sakellariou, S., Evangelou, K., Kamakari, S., Korkolopoulou, P., & Kaltsas, G. (2011) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-9-6 · Cited by 22
Cited by
Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Self-citationIto, T., Igarashi, H., Nakamura, K., Sasano, H., Okusaka, T., Takano, K., Komoto, I., Tanaka, M., Imamura, M., Jensen, R. T., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-0934-2 · Cited by 405
Self-citation
Metadata
- Authors
- Ito, T., Igarashi, H., Uehara, H., Berna, M. J., & Jensen, R. T.
- Venue
- Medicine
- Published
- 2013-05
- Volume
- 92
- Issue
- 3
- Pages
- 135-181
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W611330989
- Cited by
- 217
- References
- 6
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Causes of Death and Prognostic Factors in Multiple Endocrine Neoplasia Type 1: A Prospective Study Comparison of 106 MEN1/Zollinger-Ellison Syndrome Patients With 1613 Literature MEN1 Patients With or Without Pancreatic Endocrine Tumors. https://app.cochat.ai/papers/10.1097/md.0b013e3182954af1
- The paper
- Ito, T., Igarashi, H., Uehara, H., Berna, M. J., & Jensen, R. T. (2013). Causes of Death and Prognostic Factors in Multiple Endocrine Neoplasia Type 1: A Prospective Study Comparison of 106 MEN1/Zollinger-Ellison Syndrome Patients With 1613 Literature MEN1 Patients With or Without Pancreatic Endocrine Tumors. Medicine. https://doi.org/10.1097/md.0b013e3182954af1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.